(“NetScientific” or the “Company”)
PDS Biotechnology proposed offering
London, UK – 11 February 2020: NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq:PDSB) today made a further announcement concerning its proposed offering to raise approximately US$12 million (c.£9.3 million).
PDS mentioned in today’s announcement that, in connection with NetScientific’s expression of interest to subscribe in its offering, upon consummation of the offering it will appoint a designee of NetScientific to its board of directors.
NetScientific is considering investing £0.5 million in the offering.
A further announcement will be made as soon as appropriate
# # #
For more information, please contact:
Ian Postlethwaite, CEO and CFO
|Tel: +44 (0)20 3514 1800|
|WH Ireland Limited (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel
|Tel: +44 (0)20 7220 1666|
NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people.
For more information, please visit the website at www.NetScientific.net